Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in ...

In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type-2 inflammation or other allergic processes in phase 3 ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global ... discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi ... in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial ...

Dupilumab development program Dupilumab is being jointly developed by Sanofi ... this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval ...

Lilly’s drug becomes an oral alternative to Sanofi and Regeneron’s biologic therapy Dupixent (dupilumab ... Olumiant was approved for atopic dermatitis by the EMA last year, adding to ...